The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.
Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for a majority of malignant hematologic diseases, especially acute leukemia. HSCT from MSD offers the best results for these diseases, but lack of this donor resource has restricted its wide application. HSCT from MUD provides another option, but MUDs still cannot satisfy all patients due to unsuccessful donor searches. Almost all patients have an available related donor with whom they share a single HLA haplotype (ie, haploidentical related donor), and it owns the advantage of immediate availability, especially for those who urgently need transplantation.The results of transplantation from HRD have improved significantly over the past few years. However, the results from such haploidentical transplantation have not formally been compared with those of transplantation in patients contemporaneously using MSDs and MUDs for hematologic malignancy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
876
HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Overall Survival
The primary endpoint is overall survival within 3 years after HSCT.
Time frame: 3 year
Disease-free survival
Time frame: 3 year
Incidence of transplantation-related mortality
Time frame: 3 year
Incidence of graft-versus-host disease
Graft-versus-host disease include acute and chronic Graft-versus-host disease
Time frame: 3 year
Incidence of infection
Infection includes bacterial, fungal and viral infections.
Time frame: 3 year
hematopoietic reconstruction
Hematopoietic reconstruction includes the time of neutrophil and platelet reconstruction.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CsA is used in all the patients for GVHD prophylaxis.
MTX is used in all the patients for GVHD prophylaxis.
ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.